Aromatase (CYP19A1)
Tissue Distribution, the Obesity Connection, and the Genetics of Aromatase Excess and Deficiency
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- N/A (endogenous enzyme); aromatase inhibitors FDA-approved for breast cancer
Reference only. Not medical advice.
What can go wrong
Inappropriate aromatase-inhibitor use is the main iatrogenic risk: excessively low estradiol causes low libido, erectile dysfunction, arthralgia, dyslipidemia, and bone loss. Letrozole and anastrozole in men are off-label. The underlying obesity-aromatase mechanism is itself benign and reversible, its treatment is metabolic, not pharmacologic enzyme blockade.
This is something to take to a clinician. The Atlas can tell you what is known about aromatase (cyp19a1) in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Aromatase, encoded by the gene CYP19A1, is the enzyme that converts androgens (testosterone, androstenedione) into estrogens (estradiol, estrone). It is the only enzyme capable of making estrogen, and in men it is expressed across adipose tissue, brain, bone, testis, and skin. Adipose tissue is the dominant peripheral site, which creates the central mechanism of obesity-related hormonal change: more fat means more aromatase activity, converting more testosterone to estradiol, lowering the testosterone-to-estradiol ratio and feeding back to suppress the HPG axis. Rare human mutations bracket the enzyme's importance, aromatase DEFICIENCY (cannot make estrogen) and aromatase EXCESS syndrome (too much estrogen), and aromatase inhibitors used in oncology demonstrate the systemic consequences of fully blocking it.
The enzyme that converts testosterone into estradiol, and the reason fat tissue quietly reshapes a man's hormones.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
- Obesity-related hypogonadism
- Adipose aromatase lowers T/E2 ratio; weight loss reverses much of it
- Gynecomastia evaluation
- Aromatase-driven estrogen excess as one contributor
- Aromatase deficiency/excess
- Rare CYP19A1 disorders that bracket the enzyme's function
How it works
Aromatase performs three sequential hydroxylations that convert the A-ring of androgens into the aromatic phenolic A-ring of estrogens. Its expression is tissue-specific and promoter-driven, so 'aromatase activity' is really many locally regulated programs: brain and bone aromatase produce estrogen for local signaling, while adipose aromatase contributes much of the circulating estradiol in men. Adipose aromatase rises with fat mass and is further stimulated by inflammatory cytokines and insulin, so obesity systematically shifts the androgen/estrogen balance toward estrogen. Because estradiol is a potent negative-feedback signal on GnRH/LH, this contributes to the suppressed testosterone of obesity, a partly reversible, functional secondary hypogonadism.
Excess and deficiency: the genetics that prove the point
Two opposite Mendelian conditions define aromatase's role. AROMATASE DEFICIENCY (inactivating CYP19A1 mutations): men cannot convert testosterone to estrogen, presenting with tall stature, unfused epiphyses, low bone density, and insulin resistance despite high testosterone, corrected by estrogen, proving estradiol's necessity (Morishima, Carani 1990s). AROMATASE EXCESS SYNDROME (gain-of-function rearrangements driving CYP19A1 overexpression): excess estrogen causes prepubertal gynecomastia and accelerated then arrested bone growth (short adult stature). Between these poles sits the common, non-genetic reality: ADIPOSE aromatase in obesity. This is why the honest clinical lever for 'high estrogen' in most men is fat loss, not an aromatase inhibitor, losing adipose tissue lowers aromatization at its source while restoring testosterone, whereas an AI blocks a necessary enzyme everywhere, including bone and brain.
What people get wrong
Often saidAromatase is the enemy that steals your testosterone
ActuallyAromatase makes a NECESSARY hormone (estradiol) needed for male bone, brain, and libido. The problem in most men is not the enzyme but excess fat driving it; the fix is usually weight loss, not enzyme blockade.
Often saidAromatase inhibitors are a safe 'estrogen control' add-on for any man on testosterone
ActuallyAIs block estrogen production systemically, including in bone, and are not endorsed for routine testosterone-therapy co-prescription. Driving estradiol too low harms bone, libido, and joints.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
What we do not know
- How much of obesity-related low testosterone is fully reversible with weight loss versus requiring other intervention?
- Is there any prospectively identifiable subgroup of men who benefit from modest aromatase modulation?
- How do tissue-specific aromatase promoters explain divergent local vs circulating estradiol effects?
At a glance
- Gene
- CYP19A1 (chromosome 15)
- Function
- Only enzyme that makes estrogen from androgens
- Main male site
- Adipose tissue (plus brain, bone, testis, skin)
- Obesity effect
- More fat -> more aromatization -> lower T, higher E2
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Aromatase (CYP19A1). A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Morishima / Carani aromatase deficiency1995-1997
Men lacking aromatase had skeletal and metabolic abnormalities corrected by estrogen, proving estrogen's male role
Aromatase excess syndrome (CYP19A1 rearrangements)2000s
Gain-of-function variants cause heritable prepubertal gynecomastia and short stature
Finkelstein et al., NEJM2013
Pharmacologic aromatase blockade (anastrozole) during testosterone add-back isolated estradiol-dependent effects on fat and sexual function